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Abstract
Introduction: Rheumatism has been treated using whole-body cryotherapy (WBCT) since the 1970s. The aim of this study
was to assess the efficacy of WBCT as an experimental, adjunctive method of treating depressive and anxiety disorders.
Materials and Methods: A control (n=34) and a study group (n=26), both consisting of outpatients 18–65 years old with
depressive and anxiety disorders (ICD-10), received standard psychopharmacotherapy. The study group was additionally
treated with a series of 15 daily visits to a cryogenic chamber (2–3 min, from –160°C to –110°C). The Hamilton’s depression
rating scale (HDRS) and Hamilton’s anxiety rating scale (HARS) were used as the outcome measures.
Results: After three weeks, a decrease of at least 50% from the baseline HDRS-17 scores in 34.6% of the study group and
2.9% of the control group and a decrease of at least 50% from the baseline HARS score in 46.2% of the study group and in
none of the control group were noted. 
Conclusions: These findings, despite such limitations as a small sample size, suggest a possible role for WBCT as a short-term
adjuvant treatment for mood and anxiety disorders.
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INTRODUCTION
Treatment using total immersion of the body in
extremely low temperatures was first introduced in
Japan towards the end of the 1970s by Prof. Toshiro
Yamauchi [21], who constructed the first cryogenic
chamber and successfully used cryotherapy to treat
rheumatism. Whole-body cryotherapy (WBCT) is cur-
rently used to alleviate inflammation and pain in arthri-
tis [2] and osteoarthritis [8] and for pain relief in
fibromyalgia [10, 17]. WBCT has been found useful in
neurological diseases in reducing spasticity [20], as
a method of kinesitherapy in rheumatic diseases and
multiple sclerosis, and for its sedative effect in psoriasis
and neurodermatitis [2].
It has already been demonstrated that WBCT
applied for short times stimulates physiological reac-
tions of an organism which result in analgesic, anti-
-swelling, and hormonal, immune, and circulatory sys-
tem reactions [14, 18, 23]. When the time of exposure to
extremely low temperatures is strictly controlled,
cryotherapy does not cause any significant reactions
from the circulatory system and is thus safe [18].
Cryogenic chamber treatment does not affect heart rate,
blood pressure, or left ventricle fractional shortening
index and its ejection, or cause arrhythmia and ischemic
changes of the heart [22]. Although WBCT may induce
a transient bronchodilatory effect [1], the results of
Smolander et al. [19] did not support the hypothesis that
the WBCT improves lung function. WBCT induced
minor bronchoconstriction in healthy humans and
therefore it did not seem to be harmful to lung function.
However, WBCT should be applied with caution in sus-
ceptible individuals, such as asthmatics.
The only animal study assessed the effect of short
exposure to extremely low temperature on some plasma
and liver enzymes in rats [12]. Statistically significant
increases in the activities of glutamate dehydrogenase,
sorbitol dehydrogenase, malate dehydrogenase, orni-
thine transcarbamoylase, and arginase were observed in
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of low temperature on liver metabolism, which may lead
to changes in the metabolism of drugs.
Apart from activating the body’s system of tempera-
ture regulation, there is also a hormonal response,
which increases body metabolism and the concentra-
tions of adrenaline, noradrenaline, adrenocorticotropic
hormone (ACTH), cortisone, pro-opiomelanocortin
(POMC), and β-endorphins in blood plasma as well as
male testosterone levels [15, 23]. In a recent study
assessing blood serum concentrations of selected steroid
hormones in professional football players subjected to
WBCT, the authors suggested that it leads to a signifi-
cant decrease in serum testosterone and estradiol, with
no effect on dehydroepiandrosterone sulfate and
luteinizing hormone levels. The changes observed are
probably due to cryotherapy-induced changes in the
blood supply to the skin and subcutaneous tissue as well
as to modulation of the activity of aromatase, which is
responsible for the conversion of testosterone and
androstendione to estrogens [7].
POMC is the source of several important biologi-
cally active substances, such as ACTH in the anterior
pituitary gland and melanocyte-stimulating hormone
(α-MSH) and β-endorphin in the intermediate lobe. 
α-MSH has a role in the regulation of appetite and sex-
ual behavior. One neurobiological hypothesis of depres-
sion is based largely on dysregulation of the hypothala-
mic-pituitary-adrenal axis. The brain’s opioid peptide
systems are known to play an important role in motiva-
tion, emotion, attachment behavior, response to stress
and pain, and the control of food intake [9]. The positive
effects of WBCT in treating both external and internal
pain are due to the activation of the endogenous opioid
system and “pain control system” [15]. It is possible that
such a multi-system reaction could play a role in the
treatment of mental disorders [16]. WBCT is successful-
ly used in clinical work in several countries; however,
very limited data are available.
The aim of this study was to test the hypothesis that
WBCT may be a novel adjunctive therapy for affective
and anxiety disorders. 
MATERIALS AND METHODS
This study was based on the assessment of depressive
and anxiety symptoms observed in a group of subjects
exposed to WBCT compared with a control group. The
study, whose protocol was accepted by the local bioethics
commission, was carried out at the Department of
Psychiatry of Wroc³aw Medical University.
Subjects
Patients with any of the following conditions were
excluded from the study: circulatory or breathing insuffi-
ciency, clotting, embolism, inflammation of blood ves-
sels, open wounds, ulcers, serious cognitive disturbances,
fever, addictions, claustrophobia, and over-sensitivity to
cold. The study involved persons from 18–65 years of age
with depressive and anxiety disorders (ICD-10 criteria)
treated at an outpatient psychiatric clinic, after they had
provided written informed consent. The subjects in both
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Table 1. Sociodemographic and clinical characteristics of the samples 
Study group Control group p-value
(n=26) (n=34)
Number of females 22 (84.6%) 31 (91.2%) NS
Average age 47.04 (SD=13.05) 40.88 (SD=11.90) NS
Marital status:
single 5 (19.2%) 6 (18.2%)
in a relationship 17 (65.4%) 21 (61.8%) NS
separated/divorced 4 (15.4%) 7 (20.6%)
Number with children 17 25 NS
Number living alone 3 (11.5%) 3 (8.8%) NS
Level of education:
primary 1 1 0.001
vocational 3 17
high school 11 15
university 9 1
Number employed 7 (28.0%) 7 (20.6%) NS
Diagnosis (ICD-10):
F3 14 (53.8%) 20 (58.8%) NS
F4 12 (46.2%) 14 (41.2%)
Pharmacotherapy: NS
clasical thymoleptics 13 14
new thymoleptics 7 13
benzodiazepines 14 17
neuroleptics 5 7
NS – not significant.
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received standard psychopharmacotherapy as prescribed
by their psychiatrists (Table 1). This treatment was not
modified during the evaluation period.
Method
The subjects in the study group were additionally
treated using a cycle of 15 visits to a cryogenic chamber
carried out daily from Monday to Friday. The cryogenic
chamber has two rooms: the vestibule, in which the
temperature is –60°C, and the main chamber, where the
temperature can be set anywhere between –110 and
–160°C. The external walls are covered with multi-layer
isolation to maintain low temperatures and the outer
surface is kept at room temperature. Liquid nitrogen is
used as the coolant. The functioning of the cryogenic
chamber is entirely automated and the main working
parameters are controlled by two electronic mecha-
nisms. The sessions in the chamber lasted 2–3 min. The
temperature used in the chamber during the first visit
was –110°C. This temperature was systematically low-
ered over successive visits to permit the organism to
adapt to the low temperatures. The temperature used
during the final visit was –160°C. The patients stood
inside the chamber in swimwear with their noses and
mouths secured by a surgical mask lined on the inside
with two layers of gauze, their ears covered by a woolen
headband and their feet in woolen socks and wooden
clogs. Gregorowicz and Zagrobelny [3] provide guid-
ance on the appropriate duration of exposure and tem-
perature for adult patients as well as a list of medical
conditions for which WBCT is unsuitable.
Observations were made at six different stages: at
the start of treatment (T1), after 7, 14, and 21 days (T2,
T3, and T4, respectively), as well as 3 and 6 months after
the cycle of visits (T5 and T6, respectively). This article
considers the short-term effects of treatment (the first
three weeks, T1–T4). Apart from standard medical doc-
umentation, the study used Hamilton’s scales of depres-
sion and anxiety.
The 17-item Hamilton’s depression rating scale
(HDRS-17) is used to assess the severity of depressive
symptoms and provides a valuable guide of
a patient’s progress over time [5]. Items are scored 0–4
and, in general, the higher the total score the more
severe the depression. Questions are related to symp-
toms such as the patient’s mood, guilt feelings, thoughts
of suicide, disturbed sleep, anxiety levels, and weight
loss. The original HDRS-17 has often been reported to
be the most sensitive scale for measuring response to
treatment and is probably the most widely used scale in
research on depression for describing levels of severity
in different groups, ensuring adequate matching for
measuring improvements in clinical trials.
The Hamilton’s anxiety rating scale (HARS) was
one of the first rating scales developed to measure the
severity of anxiety symptoms [6]. The scale includes 13
symptoms regarding: moods of anxiety, tension, and
fear, insomnia, cognitive changes, depression, and
somatic symptoms of a general type and of the cardio-
vascular, respiratory, gastrointestinal, genitourinary,
and autonomic systems. Each item is rated on a 5-point
scale. The measure of anxiety is the sum of the scores
for each item. The five scores are: none (0), mild (1),
moderate (2), severe (3), and very severe (4). This is
a widely used scale and an accepted outcome measure in
clinical trials.
Outcome measure
Two criteria for determining the short-term efficacy
of WBCT as an adjunctive treatment according to either
the HDRS-17 or HARS score were used. 
Criterion 1: i) a reduction in the given score should
be significantly greater in the study group than in the
control group, and ii) the mean of the given score in
the study group must be lower at the endpoint. The
first condition is insufficient as an indicator of effec-
tiveness, since it is easier to reduce a high score than
a low score. 
Criterion 2: a positive response to treatment after
three weeks according to a score was defined as at least
a 50% reduction from the baseline score at the end-
point. WBCT is considered effective if the proportion of
patients with a positive response in the study group is
significantly greater than in the control group. 
Statistical analysis
Fisher’s exact test for independence was used to test
whether there was a significant difference between the
proportions of patients showing a decrease of 50% in
these scores over a 3-week period. The Mann-Whitney
rank test for independent samples was used to compare
changes in HDRS-17 and HARS in the two groups from
the baseline scores, since these changes did not fit the
normal distribution (e.g. the hypothesis of the normali-
ty of the change from the baseline of the depression
score was rejected using the Kolmogorov-Smirnov test,
with p<0.01, p<0.05, and p<0.01 for the changes after
one, two, and three weeks, respectively). Similarly, the
Wilcoxon rank test for dependent samples was used to
test for a significant change in these scores within
a group. Linear regression was used to compare the rate
of change of these scores according to the group and
clinical variables. Regression models were also used to
assess the effects of the two methods of treatment on
the HDRS-17 and HARS scores (dependent variables),
taking into account both sociodemographic and clinical
factors (explanatory variables: age, sex, marital status,
having children, employment, diagnosis, and treatment
type). It was assumed that each variable could be asso-
ciated with the initial assessment as well as the rate of
change of the assessment.
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Sociodemographic and clinical data regarding the
patients are presented in Table 1. The only significant
difference between the groups was the level of educa-
tion. There was a large majority of females in both
groups, but there was no significant difference between
the sex proportions in the two groups (Table 1). 
In the following section, changes in the HARS and
HDRS-17 scores within the groups were analyzed using
the Wilcoxon test and comparisons of these changes
between the groups was carried out using the Mann-
Whitney test. According to the Wilcoxon test, in the first
week (T1–T2) significant decreases in the HDRS-17
(Z= –3.678, p<0.001) and HARS (Z= –3.730, p<0.001)
scores were observed in the study group, as opposed to
the control group (Z= –0.700, p>0.4 and Z= –0.778,
p>0.4, respectively). The statistical comparison of the
average decrease in the scores within groups is central to
testing the efficacy of WBCT as an adjunctive treatment.
This average decrease was significantly greater in the
study group (Z= –3.722, p<0.001 and Z= –4.346,
p<0.001, respectively). In the second week of treatment
(T2–T3) there was again a significant decrease in depres-
sive (Z= –4.160, p<0.001) and anxiety (Z= –4.379,
p<0.001) symptoms within the study group (Table 2). 
Considering the effects of treatment over the first
two weeks, these decreases were significantly greater in
the study group (Z= –6.218, p<0.001 and Z= –4.817,
p<0.001, respectively). In the third week of treatment
(T3–T4) a significant decrease in anxiety symptoms was
observed in the control group (Z= –2.307, p<0.03).
However, no such change was observed in the severity of
depressive symptoms (Z= –0.081, p>0.9). In the study
group a significant reduction was noted in both cases
(Z= –2.995, p<0.004 and Z= –3.297, p<0.002, respec-
tively). Again, these reductions were significantly
greater in the study group (depression: Z= –4.295,
p<0.001, anxiety: Z= –1.958, p=0.05). Over the first
three weeks of treatment (T1–T4) a significant decrease
was noted in the severity of anxiety (Fig. 1; control
group: Z= –3.156, p<0.003, study group: Z= –4.436,
p<0.001) and depression (control group: Z= –2.146,
p<0.033, study group: Z= –4.461, p<0.001; Fig. 2). 
Comparing the results from both groups (Table 2),
over the first three weeks of treatment the reduction of
symptoms was significantly greater in the study group
(depression: Z= –6.306, p<0.001, anxiety: Z= –5.521,
p<0.001). It should be stressed that significant decreas-
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Table 2. Changes in anxiety and depressive scores within three weeks (mean, SD)
Weeks of treatment Study group Control group p-value for
(∆ mean) (∆ mean) comparison 
of changes
Hamilton’s anxiety rating scale  1 (T1–T2) –3.12 –0.58 <0.001
2 (T2–T3) –5.00 –0.39 <0.001
3 (T3–T4) –2.77 –0.83 <0.05
Hamilton’s depression rating scale 1 (T1–T2) –2.42 +0.96 <0.001
2 (T2–T3) –6.58 –0.01 <0.001
3 (T3–T4) –2.00 –0.22 <0.001
3.00 2.00 1.00 .00
Weeks of treatment
33
30
27
24
21
18
Study
Control
group
Mean HARS ± 1SE
Fig. 1. Intensity of anxiety symptoms within the measure points
(HARS scores)
3.00 2.00 1.00 .00
Weeks of treatment
24
22
20
18
16
14
12
10
Study
Control
group
Mean HDRS ± 1SE
Fig. 2. Intensity of depressive symptoms within the measure points
(HDRS-17 scores).
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ing each week. Such reductions were only observed in
the control group after three weeks. Also, the decrease
in both scores was very significantly greater in the con-
trol group. A decrease of 50% from the baseline scores
of depressive symptoms was noted in 34.6% (n=9) of
the study group and only in 2.9% (n=1) of the control
group (p<0.01, Fisher’s test). Such a reduction in anxi-
ety symptoms was noted in 46.2% (n=12) of patients
from the study group and none from the control group
(p<0.001, Fisher’s test). 
According to the regression model describing the
level of anxiety symptoms, the type of treatment was the
only factor associated with the rate of decrease of the
anxiety score (3.88 units/week; |t|=5.52, p<0.001),
whereas in the control group the rate of decrease was
insignificant. Additionally, the association between the
rate of decrease and the use of cryotherapy was the
strongest association according to the model (it had the
largest |t| value). According to the model describing
the severity of depressive symptoms, only the type of
treatment was associated with the rate at which the
depression score decreased. In the study group the
decrease rate was 4.15 units/week (|t|=8.83, p<0.001),
whereas in the control group the decrease rate was
insignificant. As in the model describing the anxiety
score, the association between the decrease rate and the
use of cryotherapy was the strongest. 
The fact that the decrease rate of the scores in the
control group was not significant may well be due to the
fact that the decrease was not linear. This does not con-
tradict the fact that there were significant decreases in
these scores in the control group. However, the regres-
sion analysis does indicate that the decreases in these
scores were significantly greater in the study group.
DISCUSSION
The standard and most common method of biologi-
cal treatment in psychiatry is currently the use of med-
ications. However, a considerable percentage of
patients do not respond positively and pharmacothera-
py does not lead to remission. Research is being carried
out into other, non-pharmacological strategies of treat-
ment. Phototherapy was introduced at the beginning of
the 1980s and has proved to be an effective method in
treating the seasonally occurring mood disorder occur-
ring in bipolar disorders. Electroconvulsive therapy is
still in use. Other modern biological treatment methods
are being developed. Methods involving neurostimula-
tion include repetitive transcranial magnetic stimula-
tion, magnetic seizure therapy, vagus nerve stimulation,
deep brain stimulation and transcranial direct current
stimulation. These methods may be effective in treating
depression and have minimal side effects [4, 11, 13]. 
This study was aimed at investigating whether
WBCT could be an effective aid to psychopharmaceuti-
cal treatment. No previous research has been carried
out on the efficacy of cryotherapy in psychiatric treat-
ment. The results suggest that cryotherapy may play
a positive role in the process of treating patients with
affective and anxiety disorders, since the decreases in
the HARS and HDRS-17 scores were clearly greater in
the study group than in the control group. A positive
effect was already observable after one week of treat-
ment and improvements continued to be significant over
the whole three-week cycle of cryotherapy. A significant
improvement, taken to be a decrease of at least 50%
from the baseline severity of symptoms, was observed in
almost half of the study group and only in one case in
the control group. Analysis of the long-term observa-
tions will indicate whether this effect is long lasting.
Even if the follow-up results indicate that the long-term
effects of treatment are the same in both groups, the
rapid initial improvement achieved using cryotherapy
means that such adjunctive treatment may be of value. 
The physiological mechanisms of WBCT mentioned
in the Introduction, particularly those associated with
the HPA axis and endogenous opioids, can be an expla-
nation of the positive effect of WBCT on mood. Other
unknown or unrecognized phenomena may be associat-
ed with the WBCT effect.
There is a possibility that WBCT only improves sev-
eral symptoms among the many psychopathological
phenomena associated with depressive or anxiety disor-
ders. It can be suspected that WBCT provides pain
relief and regulation of biological rhythms, which are
common symptoms accompany emotional disorders;
however, these hypotheses need to be confirmed in fur-
ther studies.
Nevertheless, despite the positive results of the
study, we are aware of its limitations. Among these one
should mention the small sample size and the lack of
a procedure randomly assigning patients to a group. We
should also note the problem of recruiting patients to
undergo a novel, unknown treatment requiring daily
mobilization and adaptation to the rigors of a research
program. Further studies are being planned involving
such methods as neuro-imaging and biochemical mea-
sures with the aim of clarifying the effect of WBCT on
mental health. There is ever-increasing interest in non-
pharmacological strategies to treat depressive disorders.
Several approaches are currently being investigated as
novel forms of therapy and may well constitute new
effective treatments for major depression.
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